ImmunityBio’s stock is up after its off-the-shelf allogeneic CD19 chimeric antigen receptor natural killer cell therapy ...

US biotech ImmunityBio has reported two ongoing complete remissions lasting seven and 15 months in patients with Waldenstrom ...

A pair of patients with Waldenstrom’s non-Hodgkins lymphoma (NHL) remain in complete remission (CR) after 7 and 15 months ...

Friday, ImmunityBio said the two complete responses are ongoing after seven and 15 months. The patients received four cycles ...

Durable complete responses with CAR-NK + Rituximab in patients who failed current standards of care in Waldenstrom’s ...

Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, ...

Artiva Biotherapeutics is developing NK cell immunotherapy for autoimmune disease. Early trial data in B-cell lymphoma ...

Chimeric antigen receptor natural killer (CAR-NK) cell therapy is emerging as a promising next-generation immunotherapy with ...

Hangzhou Qihan Biotech Co., Ltd. (“Qihan” or “Qihan Biotech” or “the Company”), an industry leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, ...

COEPTIS, Inc. has established GEAR Therapeutics as a majority-owned subsidiary to advance its GEAR-modified natural killer (NK) cell therapy into first-in-human studies targeting various cancers and ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...